The FDA has ordered a recall of a single lot of Xanax XR after discovering a dissolution flaw. Viatris, the U.S. distributor, says the 3 mg extended‑release tablets may not dissolve properly, risking uneven absorption. Regulators deem the patient risk negligible and report no adverse events. The recall covers only the extended‑release formulation, not immediate‑release versions.

Bottles containing 60 pills carry lot number 8177156 and an expiration of Feb. 28, 2027. They were shipped nationwide between August 2024 and May 2025. The recall isolates only this branded batch; generic alprazolam supplies remain untouched, and pharmacies have been instructed to pull the stock. Pharmacies have been given a 48‑hour window to remove the product. Consumers who may have purchased the medication are advised to retain the packaging for verification.

Viatris declined to disclose how many bottles the lot comprises, but the limited distribution suggests a modest financial hit. Analysts project a small write‑off against the company’s quarterly results, as Xanax XR accounts for a fraction of Viatris’s overall sales, which are dominated by generic formulations. The company’s insurance carriers are unlikely to adjust premiums based on this isolated issue.

The episode highlights the vulnerability of premium‑priced anxiolytics to manufacturing glitches. While the recall does not affect the broader market for alprazolam, investors will watch Viatris’s quality‑control investments and any ripple effects on prescribing habits. For now, patients are urged to consult pharmacists before changing therapy. Regulators will monitor compliance and may issue guidance for future extended‑release products.